Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.60 |
| ▸ | CES1 | P23141 | 4/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865398 | 0.97 | CES2 (0.64) | CES2CES1ALDH1A1TSHRSLC22A6 | |
| SCHEMBL4860910 | 0.97 | CES2 (0.64) | CES2CES1ALDH1A1TSHRSLC22A6 | |
| SCHEMBL4863249 | 0.97 | CES2 (0.64) | CES2CES1ALDH1A1TSHRSLC22A6 | |
| SCHEMBL3178705 | 0.97 | CES2 (0.64) | CES2CES1ALDH1A1TSHRSLC22A6 | |
| SCHEMBL9464032 | 0.90 | CES2 (0.56) | CES2CES1AKR1B1 | |
| SCHEMBL5936351 | 0.88 | CES2 (0.59) | CES2CES1ALDH1A1TSHRSLC22A6 | |
| SCHEMBL9057797 | 0.88 | CES2 (0.59) | CES2CES1ALDH1A1TSHRSLC22A6 | |
| SCHEMBL2734730 | 0.88 | CES2 (0.59) | CES2CES1ALDH1A1TSHRSLC22A6 | |
| SCHEMBL9054385 | 0.88 | CES2 (0.59) | CES2CES1ALDH1A1TSHRSLC22A6 | |
| SCHEMBL11784529 | 0.88 | CES2 (0.59) | CES2CES1ALDH1A1TSHRSLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452551-B1 | Targeted compositions for diagnostic and therapeutic use | IMARX THERAPEUTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7329402-B2 | Methods of imaging and treatment | IMARX PHARMACEUTICAL CORP. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1365805-A2 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | Imarx Therapeutics, Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030157025-A1 | Novel methods of imaging and treatment with targeted compositions | UNGER EVAN C (US) | 2003-08-21 | — | — | US | disclosed |
| US-6521211-B1 | Administering gases and ligand mixtures encapsulated in vesicles, scanning with ultrasonic frequency to oscillateand collapse the micelles, then detecting the reflected signals; medical diagnosis | BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. | 2003-02-18 | — | — | US | disclosed |
| WO-2002036161-A2 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX THERAPEUTICS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030157025-A1 | Novel methods of imaging and treatment with targeted compositions | FABP3, PLAUR, ASGR1 | CES2 4467/4885CES1 3662/4885AKR1B1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.